Advertisement
Advertisement
U.S. Markets open in 7 hrs 3 mins
Advertisement
Advertisement
Advertisement
Advertisement

iTeos Therapeutics, Inc. (ITOS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
27.01-0.24 (-0.88%)
At close: 04:00PM EDT
Advertisement

iTeos Therapeutics, Inc.

321 Arsenal Street
Suite 301 Building 312
Cambridge, MA 02472-5710
United States
339 217 0161
https://www.iteostherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees94

Key Executives

NameTitlePayExercisedYear Born
Dr. Michel Detheux Ph.D.Pres, CEO & Director936.5kN/A1966
Mr. Matthew A. Call M.B.A.Chief Operating Officer626.98kN/A1973
Dr. Joanne Jenkins-Lager M.D.Chief Medical Officer669.5kN/A1972
Mr. Matthew GallChief Financial OfficerN/AN/A1977
Dr. Yvonne McGrath Ph.D.Chief Scientific OfficerN/AN/A1974
Mr. Ryan BakerHead of Investor RelationsN/AN/AN/A
Mr. Phillipe BrantegemVice-Pres of HRN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Corporate Governance

iTeos Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement